The current financial score of Vir Biotechnology Inc is 8.94. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 238.95M, representing a year-over-year increase of 19582.54%, while its net profit experienced a year-over-year increase of 172.17%.
The current valuation score of Vir Biotechnology Inc is 7.89. Its current P/E ratio is -3.38, which is -334.55% below the recent high of 7.93 and -639.36% above the recent low of -25.00.
The current earnings forecast score of Vir Biotechnology Inc is 8.60. The average price target is 20.78, with a high of 30.00 and a low of 15.00.
The current price momentum score of Vir Biotechnology Inc is 5.46. Currently, the stock price is trading between the resistance level at 11.93 and the support level at 9.29, making it suitable for range-bound swing trading.
The current institutional shareholding score of Vir Biotechnology Inc is 7.00. The latest institutional shareholding proportion is 77.29%, representing a quarter-over-quarter decrease of 1.06%. The largest institutional shareholder is James Simons, holding a total of 1.02M shares, representing 0.01% of shares outstanding, with 29.86% increase in holdings.
The current risk assessment score of Vir Biotechnology Inc is 6.10. The company's beta value is 1.66. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.